In clinical trials of semaglutide for type 2 diabetes mellitus, patients exposed to semaglutide subcutaneous injection reported increases in amylase (hyperamylasemia) and lipase, and had a mean increase from baseline in amylase of 13% and lipase of 22%
For retatrutide specifically, as it remains an investigational medicine, any adverse events experienced within a clinical trial setting should be reported directly to the trial sponsor and principal investigator in accordance with the trial protocol
The dose is then increased every 4 weeks until the maintenance dose of 2.4 mg is reached
Peptides are also known as small proteins that target metabolism, hunger, and fat loss, making them a promising tool for supporting weight loss efforts and enhancing metabolic functions
Prior to seeing your medical provider, we recommend checking your plans benefits to see if weight loss medicine is covered, and if so, for what particular diagnoses